
FDA Oncology Actions: March 2025 Approvals and Designations
In March 2025, the FDA made significant strides in oncology, approving a number of agents across cancer types. The FDA started off the month approving 2 denosumab biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and Osenvelt, expanding treatment options for …